enVVeno Medical Corp (NVNO) director awarded 135,883 options on December 11, 2025
Rhea-AI Filing Summary
enVVeno Medical Corp reported a new stock option grant to a director. On December 11, 2025, the director received 135,883 stock options with an exercise price of $0.325 per share, expiring on December 11, 2035.
The options were issued under the Amended and Restated 2016 Omnibus Incentive Plan and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 135,883 | $0.00 | -- |
Footnotes (1)
- [object Object]
FAQ
What insider transaction did enVVeno Medical Corp (NVNO) report in this filing?
The filing reports that a director of enVVeno Medical Corp received 135,883 stock options on December 11, 2025 as a new equity award.
What are the key terms of the 135,883 enVVeno Medical (NVNO) stock options?
The director’s award consists of 135,883 stock options with an exercise price of $0.325 per share and an expiration date of December 11, 2035.
How do the new enVVeno Medical (NVNO) director stock options vest?
The options are subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
Under which plan were the enVVeno Medical (NVNO) stock options granted?
The options were granted under the issuer’s Amended and Restated 2016 Omnibus Incentive Plan, as amended, which governs this equity compensation award.
How many derivative securities does the enVVeno Medical (NVNO) director hold after this transaction?
Following the reported transaction, the director beneficially owns 135,883 derivative securities in the form of stock options, held with direct ownership.